在乳腺癌中准CDK4/6
Anusha Shanabag1, Jessica Armand1,2, Eugene Son1
1Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.
Experimental & molecular medicine
|February 10, 2025
概括
循环素依赖性激酶4和6 (CDK4/6) 抑制剂对于治疗激素受体阳性乳腺癌至关重要. 了解和克服耐药性对于改善患者的治疗结果和提高治疗疗效至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 循环素依赖性激酶4和6 (CDK4/6) 的过度激活导致乳腺癌的进展.
- CDK4/6抑制剂通过向细胞周期进展,彻底改变了激素受体阳性乳腺癌的治疗方法.
研究的目的:
- 审查乳腺癌细胞循环调节的分子机制.
- 检查CDK4/6抑制剂的临床应用.
- 阐明对CDK4/6抑制剂耐药性的机制,并讨论克服它们的策略.
主要方法:
- 关于分子机制的文献综述.
- 对CDK4/6抑制剂的临床试验数据的分析.
- 探索耐药性途径和新兴生物标志物的探索.
主要成果:
- 不调节的细胞循环机制,特别是CDK4/6,是乳腺癌的核心.
- CDK4/6抑制剂显示出显著的临床成功,但面临抗药性挑战.
- 缺乏预测性生物标志物阻碍了个性化治疗策略.
结论:
- 对抗性机制的进一步研究对于优化CDK4/6抑制剂治疗至关重要.
- 确定预测性生物标志物将指导治疗决策并改善患者的治疗结果.
- 开发克服耐药性的策略是提高乳腺癌治疗疗效的关键.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


